Incidence and Risk of Catheter-Related Thrombosis in Breast Cancer Patients With Implanted Ports.

IF 2.9 Q1 NURSING

Journal of Infusion Nursing Pub Date : 2025-03-01 Epub Date: 2025-03-03 DOI:10.1097/NAN.0000000000000582

Zebing Luo, Wanzhu Xu, Zhijun Guo, Manjia Xu, Xinxian Lv, Chujun Chen

{"title":"Incidence and Risk of Catheter-Related Thrombosis in Breast Cancer Patients With Implanted Ports.","authors":"Zebing Luo, Wanzhu Xu, Zhijun Guo, Manjia Xu, Xinxian Lv, Chujun Chen","doi":"10.1097/NAN.0000000000000582","DOIUrl":null,"url":null,"abstract":"Objective: This study assessed the risk factors for thrombosis related to totally implantable venous access ports (TIVAPs) among breast cancer patients.Methods: A single-center, retrospective, observational study was conducted. Demographic, disease-related, hematological, and TIVAP-related factors were assessed. Multiple logistic regression analysis was used to explore the influencing factors of TIVAP-related thrombosis.Results: A total of 416 patients with breast cancer with TIVAPs were divided into 3 groups: no thrombosis (64.4%), asymptomatic thrombosis (32.3%), and symptomatic thrombosis (3.3%). Multiple logistic regression showed that with no thrombosis as the reference, the protective factors for asymptomatic thrombosis were chemotherapy and TIVAP placement in the left side of the chest wall. Risk factors were ≤1 comorbidity and the use of ceramics as the base material of the TIVAP reservoir. With no thrombosis as the reference, cancer clinical stage III and chemotherapy were identified as protective factors of symptomatic thrombosis.Conclusion: Among breast cancer patients with a TIVAP, 32.3% had asymptomatic thrombosis and 3.3% had symptomatic thrombosis. Clinical staff should pay close attention to these indicators and identify high-risk patients with TIVAP-related thrombosis as early as possible.","PeriodicalId":46291,"journal":{"name":"Journal of Infusion Nursing","volume":" ","pages":"114-122"},"PeriodicalIF":2.9000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Infusion Nursing","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/NAN.0000000000000582","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/3 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"NURSING","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This study assessed the risk factors for thrombosis related to totally implantable venous access ports (TIVAPs) among breast cancer patients.

Methods: A single-center, retrospective, observational study was conducted. Demographic, disease-related, hematological, and TIVAP-related factors were assessed. Multiple logistic regression analysis was used to explore the influencing factors of TIVAP-related thrombosis.

Results: A total of 416 patients with breast cancer with TIVAPs were divided into 3 groups: no thrombosis (64.4%), asymptomatic thrombosis (32.3%), and symptomatic thrombosis (3.3%). Multiple logistic regression showed that with no thrombosis as the reference, the protective factors for asymptomatic thrombosis were chemotherapy and TIVAP placement in the left side of the chest wall. Risk factors were ≤1 comorbidity and the use of ceramics as the base material of the TIVAP reservoir. With no thrombosis as the reference, cancer clinical stage III and chemotherapy were identified as protective factors of symptomatic thrombosis.

Conclusion: Among breast cancer patients with a TIVAP, 32.3% had asymptomatic thrombosis and 3.3% had symptomatic thrombosis. Clinical staff should pay close attention to these indicators and identify high-risk patients with TIVAP-related thrombosis as early as possible.

查看原文本刊更多论文

乳腺癌导管植入患者导管相关血栓形成的发生率及风险。

目的：探讨全植入式静脉通路（TIVAPs）对乳腺癌患者血栓形成的危险因素。方法：采用单中心、回顾性观察性研究。评估人口统计学、疾病相关、血液学和tivap相关因素。采用多元logistic回归分析探讨tivap相关血栓形成的影响因素。结果：416例采用TIVAPs的乳腺癌患者分为无血栓形成（64.4%）、无症状血栓形成（32.3%）、有症状血栓形成（3.3%）3组。多元logistic回归分析显示，在无血栓形成为参照的情况下，化疗及在左侧胸壁放置TIVAP是无症状血栓形成的保护因素。危险因素为合并症≤1，并使用陶瓷作为TIVAP储层的基材。以无血栓形成为参照，确定肿瘤临床III期及化疗是症状性血栓形成的保护因素。结论：在采用TIVAP的乳腺癌患者中，无症状血栓形成占32.3%，有症状血栓形成占3.3%。临床工作人员应密切关注这些指标，尽早发现与tivap相关的血栓形成高危患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Infusion Nursing NURSING-

CiteScore

4.00

自引率

15.00%

发文量

期刊介绍： Journal of Infusion Nursing, the official publication of the Infusion Nurses Society (INS), seeks to promote excellence in infusion nursing by presenting new research, clinical reviews, case studies, and professional development information relevant to the practice of infusion therapy. Articles selected for publication represent the broad scope of the infusion specialty and draw on the expertise of all healthcare providers who participate in the delivery of infusion therapy.